Digital Therapeutics Patents: Who Leads, Where the Gaps Are 2026
- Concentrated but not locked. The top 5 assignees hold 42.9% of all 238 records in scope, yet the tenth-ranked filer has just 7 — a long tail follows the leader.
- Growth cooled after 2021. Filings ran 33 in 2021 to 27 in 2024, an 18% pullback over that span, after peaking at 47 in 2022.
- Healthcare informatics dominates the claims. G16H appears on 72.7% of the 238 records, far ahead of diagnosis/surgery (A61B, 28.2%) and AI-based computing (G06N, 22.3%).
Filing growth compares 2021 (33 records) with 2024 (27) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 238 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This review covers 238 published patent records filed or published between 2015 and the 2026 data cut-off, drawn from filings that combine digital therapeutics language with clinical or delivery-mechanism terms such as dosage composition, binding assay, therapeutic response and health record. The scope spans software-defined interventions, decision-support tooling and the delivery infrastructure around them, rather than digital health broadly. Publication lags filing by roughly 18 months, so the 2025 and 2026 counts in any trend understate the true filing volume for those years.
Records were pulled from receiving offices led by the United States, followed by WIPO's PCT route, the EPO and India, with smaller volumes at the Canadian and Australian offices. That distribution points to a field still filing primarily for US protection while testing international routes through PCT rather than committing broadly to multiple national offices early.
Filing trends and technology composition
The two views below use the same 238-record scope: one tracks filings by year, the other breaks the corpus down by IPC subclass. Because a single record can carry more than one IPC class, the technology shares add up to more than 100%.
A decade of uneven growth
Filings rose from 5 in 2017 to a peak of 47 in 2022, then eased to 27 by 2024 — an 18% decline over the 2021-2024 window. The 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a continued slowdown.
Healthcare informatics anchors the field
G16H (healthcare informatics) appears on 72.7% of the 238 records, well ahead of A61B (diagnosis and surgery, 28.2%) and G06N (AI-based computing, 22.3%). Smaller but present classes — A61K medicinal preparations, A61P therapeutic activity, H04L digital transmission and C07D heterocyclic compounds — mark where digital therapeutics claims intersect with drug-delivery and communications-layer patenting.
Shares are the percentage of the 238 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Digital Therapeutics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about digital therapeutics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
Digital therapeutics management system and method of operating the same
The system receives prescription information for digital therapeutics from a medical institution's terminal, provides that prescription to a user's terminal, collects execution result information back from the user, and relays it to the medical institution while a record manager maintains the treatment history.Filed as US12512198B2, granted to ODN CO., LTD, dated 2025-12-30 — illustrates the prescription-to-execution data loop that recent filings in this space are built around.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US11056242B1 | Predictive analysis and interventions to limit disease exposure | 184 |
| 2 | US11504011B1 | Early detection and prevention of infectious disease transmission using location data and geofencing | 104 |
| 3 | US11342051B1 | Infectious disease monitoring using location information and surveys | 103 |
| 4 | US20220215948A1 | Network-based medical apparatus control and data management systems | 95 |
| 5 | US11102304B1 | Delivering information and value to participants in digital clinical trials | 93 |
| 6 | US11127506B1 | Digital health tools to predict and prevent disease transmission | 81 |
| 7 | US20190313934A1 | Device and system for monitoring and treating muscle tension-related medical conditions | 65 |
| 8 | US11456080B1 | Adjusting disease data collection to provide high-quality health data to meet needs of different communities | 60 |
| 9 | US11522703B1 | Decentralized applications and data sharing platform for clinical research | 44 |
| 10 | US11789837B1 | Adaptive data collection in clinical trials to increase the likelihood of on-time completion of a trial | 41 |
Citation counts favour older records in the corpus and should be read as a signal of influence rather than current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, the trend and the IPC composition are read together.
The lead is real but not a wall
The top 5 assignees combined hold 42.9% of all 238 records in scope, and the top 10 hold 61.3%. But the leader's 30 records against a fifth-place count of 14 and a tenth-place count of 7 shows a fast drop-off — this is a field with one clear leader and a long tail of smaller filers, not a closed oligopoly.
Growth peaked, then corrected
Filings climbed from 5 in 2017 to a peak of 47 in 2022, then fell to 27 by 2024, an 18% decline over that three-year span. Because publication lag means 2025-2026 data is still incomplete, this reads as a correction off a 2022 peak rather than a confirmed multi-year decline.
Informatics claims dominate the corpus
G16H healthcare informatics touches nearly three-quarters of the 238 records, with A61B diagnosis/surgery and G06N AI-based computing as the next-densest classes. Smaller classes like A61K and A61P mark a genuine but minority overlap with drug-delivery patenting inside a software-first field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to digital therapeutics patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Mahana Therapeutics Inc | LEVY SIMON | 6 |
| Mahana Therapeutics Inc | BASTA STEVEN | 6 |
| Mahana Therapeutics Inc | MILLER JULIE | 4 |
| Mahana Therapeutics Inc | MONTGOMERY ANN HARRIET | 3 |
| Astrocyte Pharmaceuticals Inc | United States Government, as represented by the Secretary of Health and Human Services | 3 |
| Mahana Therapeutics Inc | WATSON NOREEN | 2 |
| Mahana Therapeutics Inc | KRAICH KAYLA | 2 |
| Mahana Therapeutics Inc | SCHREINER AMY | 1 |
Only 8 co-assignee pairs appear in the dataset, and the strongest pairs cluster around a single leading assignee working with named individual co-inventors — evidence of tightly held internal collaboration rather than cross-company joint filing.
Who is filing, and where the gate sits
The assignee ranking returned by the data endpoint covers 100 companies, not a curated top list — treat the ranked positions as the whole visible field for this search rather than a subset of a larger population.
One filer sets the pace
The leading assignee's 30 records is more than double the fifth-place count of 14, giving it outsized visibility across the corpus even though it does not approach a majority share on its own.
The drop into the mid-tier is steep
By the tenth position, counts have fallen to 7 — under a quarter of the leader's total. That gap suggests a handful of well-resourced filers followed by many entrants filing in single digits.
Momentum has gone quiet at the top
Several of the most-active historical assignees show zero filings in the latest year, with year-over-year drops of 100% for some; only one tracked assignee shows any latest-year activity, at 2 filings flat year-over-year. Read this alongside publication lag rather than as evidence the leaders have exited.
| Assignee | Recent year | YoY |
|---|---|---|
| Click Therapeutics Inc | 2 | 0% |
| VIGNET INC | 0 | -100% |
| Mahana Therapeutics Inc | 0 | — |
| WellDoc Inc | 0 | -100% |
| Abiomed Inc | 0 | — |
| CAREMETX LLC | 0 | -100% |
| Cedars-Sinai Medical Center | 0 | — |
| Astrocyte Pharmaceuticals Inc | 0 | — |
Where to take this next
The dataset points to specific follow-up questions rather than a single verdict on the field.
Track the 2025-2026 correction
Because publication lag leaves the most recent two years incomplete, confirming whether the post-2022 pullback continues requires revisiting this trend once those years finish publishing.
Explore filing trends in EurekaMap the long tail
With 61.3% of records held outside the top 10, a large share of activity sits with smaller filers whose specific claim scope is worth checking individually before filing nearby.
Search assignees in EurekaCheck white space before drafting
The thinner classes — C07D, H04L, A61P — mark where digital therapeutics claims have not yet crowded out drug-delivery or communications-layer approaches.
Run a white space search in EurekaCommon questions about digital therapeutics patents
This dataset scope contains 238 published patent records filed or published between 2015 and the August 2026 data cut-off. The count spans filings that combine digital therapeutics terminology with clinical or delivery-mechanism language such as dosage composition, therapeutic response and health record. Because publication typically lags filing by around 18 months, the totals for 2025 and 2026 are still incomplete and will rise as more filings publish.
The ranking returned by the data covers 100 companies, with the leading assignee holding 30 records against a fifth-place count of 14 and a tenth-place count of 7. That gap shows a single clear leader followed by a fast drop-off into a long tail of smaller filers, rather than a market split evenly among several equally sized players. The top 5 assignees combined account for 42.9% of all 238 records in scope, and the top 10 for 61.3%.
Filings rose from 5 in 2017 to a peak of 47 in 2022, then declined to 27 by 2024 — an 18% drop over that three-year span. That pattern reads as a correction off a strong 2022 peak rather than a structural slowdown, since 2025-2026 figures are not yet complete due to publication lag. Anyone using this trend for forecasting should treat the most recent two years as provisional.
Healthcare informatics, IPC class G16H, appears on 72.7% of the 238 records in scope, making it by far the densest claim area. Diagnosis and surgery (A61B, 28.2%) and AI-based computing (G06N, 22.3%) follow well behind. Smaller classes covering medicinal preparations, therapeutic activity and heterocyclic compounds show a real but minority overlap with drug-delivery patenting inside what is largely a software-first field.
The thinner IPC classes in this corpus — heterocyclic compounds (C07D, 4.6%), digital information transmission (H04L, 5.5%) and therapeutic activity of compounds (A61P, 7.6%) — mark branches with comparatively little filing density relative to the dominant informatics and AI classes. Specific under-claimed combinations include binding-assay integration with software prescriptions and cross-border health-record interoperability. These are candidates for further prior-art checking before drafting, not confirmed gaps, since low density in an IPC class can also reflect fewer applicable inventions rather than open opportunity.
Research Digital Therapeutics Patent Landscape in depth with Eureka
Go past this page: query the whole digital therapeutics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.